12:00 AM
 | 
Nov 05, 2012
 |  BioCentury  |  Strategy

Orphanage in Asia

Alnylam piggybacks on Genzyme's Orphan presence in Japan with TTR program

When Alnylam Pharmaceuticals Inc. decided to find an Asian partner for its lead "5x15" RNAi program, Sanofi's Genzyme Corp. unit emerged as the best option due to its Orphan network in Japan and Sanofi's commitment in other emerging Asian markets.

Alnylam launched its 5x15 initiative in January 2011 with the goal of moving five internal RNAi programs into clinical development for genetically defined diseases by 2015.

The most advanced program involves a pair of RNAi products to treat transthyretin (TTR)-mediated amyloidosis, the toxic accumulation of the protein in various tissues including nerves, heart, and gastrointestinal tract. Intravenous ALN-TTR02 is in Phase II testing and subcutaneous ALN-TTRsc is in preclinical development.

In considering how to balance the need...

Read the full 592 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >